Prognosis
EU Likely to Drop AstraZeneca, J&J as Future Vaccine Options
- French minister says contracts unlikely to be resumed
- EU is prioritizing mRNA vaccines, such as Pfizer/BioNTech
A health worker administers the Moderna Inc. Covid-19 vaccine at a center in Rome.
Photographer: Alessia Pierdomenico/BloombergThis article is for subscribers only.
The European Union “most probably” won’t renew contracts for Covid-19 vaccines with AstraZeneca Plc and Johnson & Johnson as it prioritizes other types of shots, according to a French government minister.
The comments follow the European Commission’s announcement this week that it’s in talks with Pfizer Inc. and BioNTech for as many as 1.8 billion additional vaccine doses through 2023.